Corvus Pharmaceuticals CRVS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.44M+11.0% | $33.72M+13.3% | $29.75M+12.2% | $26.52M+16.5% | $22.76M+17.4% | ||
| $10.49M+13.3% | $9.25M+1.6% | $9.11M+0.9% | $9.02M+6.7% | $8.45M+3.6% | ||
| $47.93M+11.5% | $42.97M+10.6% | $38.86M+9.3% | $35.54M+13.9% | $31.22M+13.3% | ||
| -$47.93M-11.5% | -$42.97M-10.6% | -$38.86M-9.3% | -$35.54M-13.9% | -$31.22M-13.3% | ||
| -$42.15M-216% | -$13.33M-14.4% | -$11.65M+71.8% | -$41.35M-10.5% | -$37.43M+36.7% | ||
| -$44.17M-189% | -$15.28M-1.4% | -$15.08M+66.6% | -$45.14M-9.0% | -$41.4M+33.5% | ||
| -$0.52-4.0% | -$0.50+2.0% | -$0.51+48.5% | -$0.99-3.1% | -$0.96-1.1% | ||
| -$47.81M-11.5% | -$42.87M-10.6% | -$38.76M-9.3% | -$35.45M-13.9% | -$31.13M-13.4% | ||
| -$47.93M-11.5% | -$42.97M-10.6% | -$38.86M-9.3% | -$35.54M-13.9% | -$31.22M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Corvus Pharmaceuticals profitable?
- Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
- What is Corvus Pharmaceuticals's earnings per share?
- Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
- Where does Corvus Pharmaceuticals's income statement data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.